



|  |  |                           |                   |
|--|--|---------------------------|-------------------|
| 449 IRSY. 7.801<br>U.S. Department of Commerce<br>Patent and Trademark Office              |  | ATTORNEY<br>DOCKET<br>NO. | 2488-1-012PCT/US  |
|  |  | SERIAL NO.                | 10/558,937        |
| LIST OF DOCUMENTARY INFORMATION<br>CITED BY APPLICANT<br>(Use several sheets if necessary) |  | APPLICANT                 | Miles Andrew NUNN |
|  |  | FILING<br>DATE            | December 1, 2005  |
|  |  | GROUP                     | Not yet assigned  |

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL |  | DOCUMENT<br>NUMBER | DATE | NAME | CLASS | SUB-<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--|--------------------|------|------|-------|---------------|-------------------------------|
|                     |  |                    |      |      |       |               |                               |
|                     |  |                    |      |      |       |               |                               |
|                     |  |                    |      |      |       |               |                               |

## FOREIGN PATENT DOCUMENTS

|          |    | DOCUMENT<br>NUMBER | DATE   | COUNTRY | CLASS | SUB-<br>CLASS | TRANSLATION<br>YES NO |
|----------|----|--------------------|--------|---------|-------|---------------|-----------------------|
| /H.A.R./ | BA | WO 93/17099        | 9/2/93 | PCT     | —     | —             |                       |
|          |    |                    |        |         |       |               |                       |
|          |    |                    |        |         |       |               |                       |

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

|          |    |   |
|----------|----|---|
| /H.A.R./ | CA | Bao et al., Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice, <i>J. Immunol.</i> , 168:3601-3607 (2002)                   |
|          | CB | Bedford et al., Influence of complement depletion on sperm function in the female rabbit, <i>J. Reprod. Fertil.</i> , 69:523-528 (1983)   |
|          | CC | Bioscik et al., Derivation of RNA aptamer inhibitors of human complement C5, <i>Immunopharmacology</i> , 42:219-230 (1999)  |
| ↓        | CD | Ciochetti et al., Combined Inhibition of Apoptosis and Complement Improves Neural Graft Survival of Embryonic Rat and Porcine Mesecephalon in the Rat Brain, <i>Exp. Neurol.</i> , 177:376-384 (2002) |

|   |                 |                  |            |
|---|-----------------|------------------|------------|
| EXAMINER:   | /Hope Robinson/ | DATE CONSIDERED: | 04/11/2009 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;<br>Draw line through citation if not in conformance and not considered. Include copy of this form with next<br>communication to applicant. |                 |                  |            |



|   |  |                     |                   |
|---|--|---------------------|-------------------|
| Form PTO-1449 IRSY. 7.801<br>U.S. Department of Commerce<br>Patent and Trademark Office |  | ATTORNEY DOCKET NO. | 2488-1-012PCT/US  |
|   |  | SERIAL NO.          | 10/558,937        |
| LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT<br>(Use several sheets if necessary) |  | APPLICANT           | Miles Andrew NUNN |
|   |  | FILING DATE         | December 1, 2005  |
|   |  | GROUP               | Not yet assigned  |

|          |    |  |
|----------|----|--|
| /H.A.R./ | CE | Diamond et al., Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement, 3:305-312 (1995)  |
|          | CF | <del>Ember et al., Characterization of Complement Anaphylatoxins and Their Biological Responses, In: The Human Complement System in Health and Disease, Volanakis, J.E., Frank, M.M., (Eds.), Marcel Dekker, New York, 241-254</del>                     |
| /H.A.R./ | CG | Feecke et al., Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex, Xenotransplantation, 9:97-105 (2002)   |
|          | CH | Florante et al., Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models, Xenotransplantation, 8:24-35 (2001)   |
|          | CI | Fitch et al., Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass, Circulation, 100:2499-2506 (1999) |
|          | CJ | Frei et al., Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies, Molecular Cell. Probes, 1:141-149 (1987)   |
|          | CK | Giclas, P.C., Classical pathway evaluation and alternative pathway evaluation (sections 13.1 and 13.2), In: Current Protocols in Immunology, Editors: J.E. Coligan, A.M. Kruisbeek, D.H. Marguiles, E.M. Shevach and W. Strober, Vol. 3 (1994)           |
|          | CL | Homeister et al., Effects of Complement Activation in the Isolated Heart, Circulation Research, 71:303-319 (1992)  |
|          | CM | Hebelle et al., Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes, 254:102-105 (1991)   |
|          | CN | Jarvis et al., IgM rheumatoid factor and the inhibition of covalent binding of C4b to IgG in immune complexes, Clin. Exp. Rheumatol., 11:135-141 (1993)  |
| ↓        | CO | Kohli, Anaphylatoxins and infectious and non-infectious inflammatory diseases, Molecular Immunology, 38:175-187 (2001)   |

|  |                 |                  |            |
|--|-----------------|------------------|------------|
| EXAMINER:  | /Hope Robinson/ | DATE CONSIDERED: | 04/11/2009 |
| * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |                  |            |

Hope Robinson 6/11/10



|  |  |                           |                   |
|--|--|---------------------------|-------------------|
| Form PTO-1449 IRSY. 7.801<br>U.S. Department of Commerce<br>Patent and Trademark Office    |  | ATTORNEY<br>DOCKET<br>NO. | 2488-I-012PCT/US  |
|  |  | SERIAL NO.                | 10/558,937        |
| LIST OF DOCUMENTARY INFORMATION<br>CITED BY APPLICANT<br>(Use several sheets if necessary) |  | APPLICANT                 | Miles Andrew NUNN |
|  |  | FILING<br>DATE            | December 1, 2005  |
|  |  | GROUP                     | Not yet assigned  |

|          |    |   |
|----------|----|---|
| /H.A.R./ | CP | Konttinen et al., Complement In acute and chronic arthritides: assessment of C3c, C9 and proctein (CD59) in synovial membrane, Ann. Rheum. Dis., 55:888-894 (1996)  |
|          | CC | Kroshus et al., A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation, Transplantation, 69:2282-2289 (2000) |
|          | CR | Link et al., Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation, Mol. Immunol., 36:1235-1247 (1999)   |
|          | CS | Miletic, et al., Complement activation in stored platelet concentrates, Transfusion, 33:150-154 (1993)  |
|          | CT | Mulligan et al., Endothelial Targeting and Enhanced Antiinflammatory Effects of Complement Inhibitors Possessing Sialyl Lewis <sup>x</sup> Moieties, J. Immunol., 162:4952-4959 (1999)  |
|          | CU | Paesen et al., Tick Histamine-Binding Proteins: Isolation, Cloning, and Three-Dimensional Structure, Molecular Cell, 3:661-671 (1999)   |
|          | CV | Paesen et al., Tick histamine-binding proteins: Iipocalins with a second binding cavity, Biochim. Biophys. Acta., 1482:92-101 (2000)  |
|          | CW | Pratt et al., Effects of Complement Inhibition with Soluble Complement Receptor-1 on Vascular Injury and Inflammation during Renal Allograft Rejection in the Rat, Am. J. Pathol., 149:2055-2066 (1996)                       |
|          | CX | Rehrig et al., Complement Inhibitor, Complement Receptor 1-Related Gene/Protein γ-Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice, J. Immunol., 167:5921-5927 (2001)        |
|          | CY | Ribeiro, Ixodes dammini: Salivary Anti-complement Activity, Exp. Parasitol., 64:347-353 (1987)  |
| ↓        | CZ | Rollins et al., Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement- Strategies for Evading the Humoral Immune Response, Hum. Gene Ther., 7:619-626 (1996)                  |

|   |                             |
|---|-----------------------------|
| EXAMINER: /Hope Robinson/   | DATE CONSIDERED: 04/11/2009 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;<br>Draw line through citation if not in conformance and not considered. Include copy of this form with next<br>communication to applicant. |                             |



|  |  |                           |                   |
|--|--|---------------------------|-------------------|
| Form PTO-1449 IRSY. 7.801<br>U.S. Department of Commerce<br>Patent and Trademark Office    |  | ATTORNEY<br>DOCKET<br>NO. | 2488-1-012PCT/US  |
|  |  | SERIAL NO.                | 10/558,937        |
| LIST OF DOCUMENTARY INFORMATION<br>CITED BY APPLICANT<br>(Use several sheets if necessary) |  | APPLICANT                 | Miles Andrew NUNN |
|  |  | FILING<br>DATE            | December 1, 2005  |
|  |  | GROUP                     | Not yet assigned  |

|          |    |   |
|----------|----|---|
| /H.A.R./ | DA | Rollins et al., Anti-C5 Single Chain Antibody Therapy Blocks Complement & Leukocyte Activation and Reduces Myocardial Tissue Damage in CPB Patients, <i>Mol. Immunol.</i> , 35:397-397 (1998)                       |
|          | DB | Sahu et al., Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics, <i>Immunopharmacology</i> , 49:133-148 (2000)  |
|          | DC | Sandoval et al., Distal Recognition Site for Classical Pathway Convertase Located in the C345C/Netrin Module of Complement Component C5, <i>The Journal of Immunol.</i> , 165:1066-1073 (2000)                      |
|          | DD | Schiller et al., Expression of a Soluble Complement Inhibitor Protects Transgenic Mice from Antibody-induced Acute Renal Failure, <i>J. Am. Soc. Nephrol.</i> , 12:71-79 (2001)                                     |
|          | DE | Smith et al., Membrane-targeted complement inhibitors, <i>Mol. Immunol.</i> , 38:249-255 (2001)   |
|          | DF | Solomon et al., Transmission of antibody-induced arthritis is independent of complement component 4(C4) and the complement receptors 1 and 2 (CD21/35), <i>Eur. J. Immunol.</i> , 32:644-651 (2002)                 |
|          | DG | Tanaka et al., Effect of Anticomplement Agent K76 COOH On Hamster-To-Rat and Guinea Pig-to-Rat Heart Xenotransplantation, <i>Transplantation</i> , 62:681-688 (1996)  |
|          | DH | Thomas et al., Sulfonated Dextran Inhibits Complement Activation and Complement-Dependent Cytotoxicity in an <i>in vitro</i> Model of Hyperacute Xenograft Rejection, <i>Mol. Immunol.</i> , 33:643-648 (1996)      |
|          | DI | Vakeva et al., Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion-Roll of the Terminal Complement Components and Inhibition by Anti-C5 Therapy, <i>Circulation</i> , 97:2259-2267 (1998) |
|          | DJ | Valenzuela et al., Purification, Cloning, and Expression of a Novel Salivary Anticomplement Protein from the Tick, <i>Ixodes scapularis</i> , <i>J. Biol. Chem.</i> , 275:18717-18723 (2000)                        |
| ▼        | DK | Wang et al., Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease, <i>Proc. Natl. Acad. Sci. USA</i> , 92:8955-8959 (1995)                                   |

|   |                 |                  |            |
|---|-----------------|------------------|------------|
| EXAMINER:   | /Hope Robinson/ | DATE CONSIDERED: | 04/11/2009 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |                  |            |



|  |  |                           |                   |
|--|--|---------------------------|-------------------|
| Form PTO-1449 IRSY. 7.801<br>U.S. Department of Commerce<br>Patent and Trademark Office    |  | ATTORNEY<br>DOCKET<br>NO. | 2488-1-012PCT/US  |
| LIST OF DOCUMENTARY INFORMATION<br>CITED BY APPLICANT<br>(Use several sheets if necessary) |  | SERIAL NO.                | 10/558,937        |
|  |  | APPLICANT                 | Miles Andrew NUNN |
|  |  | FILING<br>DATE            | December 1, 2005  |
|  |  | GROUP                     | Not yet assigned  |

|          |    |  |
|----------|----|--|
| /H.A.R./ | DL | Wang et al., Amelioration of lupus-like autoimmune disease in NZB/WF <sub>1</sub> mice after treatment with a blocking monoclonal antibody specific for complement component C5, Proc. Natl. Acad. Sci. USA, 93:8563-8568 (1996)   |
|          | DM | Ward et al., Use of Animal Models to Define Complement Functions, In: Contemporary Immunology: Therapeutic Interventions in the Complement System, Lambris, J.D., Hohlers, V.M. (Eds.), Humana Press, Totowa, NJ, 237-253 (2000)   |
|          | DN | Weisman et al., Soluble Human Complement Receptor Type 1: <i>In vivo</i> Inhibitor of Complement Suppressing Post-ischemic Myocardial Inflammation and Necrosis, Science, 249:148-151 (1990)   |
|          | DO | Wyss-Coray et al., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice, Proc. Natl. Acad. Sci. USA, 99:10837-10842 (2002)  |
|          | DP | Zhang et al., Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface, J. Biol. Chem., 276:27290-27295 (2001)   |
|          | DQ | McKenzie et al., Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein, J. of Infectious Diseases, 166:1245-1250 (1992)   |
|          | DR | Asghar et al., Inhibition of Complement by a Series of Substituted 2-Aryl-1, 3-Indandiones: Interaction with the Fifth Component of Complement, Molecular Immunology, 23:459-465 (1986)  |
|          | DS | White, Jr. et al., Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol, Agents and Actions, 16:385-392 (1985)  |
|          | DT | Feuillard et al., Comparative study of <i>in vitro</i> inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA), Agent and Actions, 32:343-346 (1991) |
| ↓        | DU | Baranda et al., Purification, N-terminal sequencing and diagnostic value of the major antigen of <i>Ornithodoros erraticus</i> and <i>O. moubata</i> , Veterinary Parasitology, 87:193-206 (2000)  |

|  |                 |                  |            |
|--|-----------------|------------------|------------|
| EXAMINER:  | /Hope Robinson/ | DATE CONSIDERED: | 04/11/2009 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;<br>Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |                  |            |



|  |  |                           |                   |
|--|--|---------------------------|-------------------|
| Form PTO-1449 IRSY. 7.601<br>U.S. Department of Commerce<br>Patent and Trademark Office    |  | ATTORNEY<br>DOCKET<br>NO. | 2488-1-012PCT/US  |
|  |  | SERIAL NO.                | 10/558,937        |
| LIST OF DOCUMENTARY INFORMATION<br>CITED BY APPLICANT<br>(Use several sheets if necessary) |  | APPLICANT                 | Miles Andrew NUNN |
|  |  | FILING<br>DATE            | December 1, 2005  |
|  |  | GROUP                     | Not yet assigned  |

|           |                 |                  |            |
|-----------|-----------------|------------------|------------|
| EXAMINER: | /Hope Robinson/ | DATE CONSIDERED: | 04/11/2009 |
|-----------|-----------------|------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.